A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Anaprox Patient, Information, Instructions - Naproxen Sodium
Anaprox Patient, Information, Instructions - Naproxen Sodium
PATIENT INFORMATION
Naprelan® (naproxen sodium
controlled-release tablets) represents the first prescription
product to offer convenient
once-a-day dosing of naproxen, a medication
long considered a standard in arthritis
treatment. Naproxen or naproxen sodium-based products account for
nearly one in every five prescriptions written for non-steroidal
anti-inflammatory drugs (NSAID) in the United States. (Naproxen
sodium, a sodium
salt formulation of naproxen,
provides for more rapid absorption.)
Naprelan tablets use a proprietary delivery system IPDAS™, (Intestinal
Protective Drug Absorption System), a matrix of naproxen sodium
with immediate and
controlled-release components. Upon ingestion, and after rapid disintegration
of the tablet matrix,
an initial portion (approximately 30%) of the medication
is released for rapid systemic absorption -- achieving onset of
analgesic action
within 30 minutes. In addition, a sustained-release component
of microparticles provides an extended absorption phase
that has wide GI dispersion,
allowing gradual absorption throughout the GI
tract, and prolongs therapeutic
systemic levels of
the drug, enabling 24-hour duration
of action and once-a-day
dosing.
Naproxen has been used safely and effectively worldwide for 20
years and is one of the NSAIDs
most widely used in the treatment of osteoarthritis
and rheumatoid arthritis.
Numerous clinical studies have demonstrated the efficacy
and safety profile of
naproxen. Naprelan offers the same efficacy
and safety profile with
the added advantage of once-a-day dosing. The most frequent complaints
relate to the gastrointestinal tract. Serious GI
toxicity, such
as perforation,
ulceration or bleeding
can occur in patients treated chronically with NSAID
therapy. Please consult with your physician
to see if Naprelan may be right
for you.
- Naprelan® is marketed by Wyeth-Ayerst Labratories and not
associated with Syntex Puerto Rico, Inc.
- Naproxen is a registered trademark of Syntex Puerto Rico, Inc.
- IPDAS™ is a trademark of élan pharma ltd.
- Naprelan® (naproxen sodium) Controlled Release Tablets
Equivalent to 375 mg
and 500 mg naproxen
top
